PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Short Interest Update

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) was the recipient of a large decline in short interest in February. As of February 13th, there was short interest totaling 1,503,564 shares, a decline of 18.8% from the January 29th total of 1,851,701 shares. Approximately 3.1% of the company’s stock are short sold. Based on an average trading volume of 265,492 shares, the short-interest ratio is currently 5.7 days. Based on an average trading volume of 265,492 shares, the short-interest ratio is currently 5.7 days. Approximately 3.1% of the company’s stock are short sold.

Hedge Funds Weigh In On PMV Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. BML Capital Management LLC grew its position in shares of PMV Pharmaceuticals by 33.4% during the second quarter. BML Capital Management LLC now owns 5,000,000 shares of the company’s stock worth $5,300,000 after buying an additional 1,252,388 shares in the last quarter. Acadian Asset Management LLC boosted its stake in PMV Pharmaceuticals by 0.9% during the 2nd quarter. Acadian Asset Management LLC now owns 2,066,137 shares of the company’s stock valued at $2,188,000 after acquiring an additional 18,960 shares during the last quarter. Tang Capital Management LLC boosted its stake in PMV Pharmaceuticals by 3.2% during the 4th quarter. Tang Capital Management LLC now owns 4,940,000 shares of the company’s stock valued at $6,175,000 after acquiring an additional 154,799 shares during the last quarter. Vanguard Group Inc. grew its holdings in PMV Pharmaceuticals by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,163,027 shares of the company’s stock worth $3,028,000 after acquiring an additional 9,427 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of PMV Pharmaceuticals by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 446,140 shares of the company’s stock worth $558,000 after purchasing an additional 14,320 shares during the last quarter. 90.20% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of PMV Pharmaceuticals in a research note on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, PMV Pharmaceuticals has an average rating of “Hold” and a consensus target price of $5.00.

PMV Pharmaceuticals Stock Performance

Shares of NASDAQ PMVP opened at $1.50 on Thursday. PMV Pharmaceuticals has a 1 year low of $0.81 and a 1 year high of $1.88. The stock’s 50-day simple moving average is $1.18 and its 200-day simple moving average is $1.30. The firm has a market cap of $79.82 million, a price-to-earnings ratio of -0.94 and a beta of 1.27.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.